 |
Medivation Reports Fourth Quarter and Year-End 2010 Financial Results and Provides Corporate Update
Mar 16, 2011
|
20.3 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/16/11 --
Medivation, Inc. (NASDAQ: MDVN) today
provided a corporate update and reported its financial results for the year
ended December 31, 2010.
"We are pleased with the progress we made with our MDV3100 and dimebon
programs in 2010, and we look forward to reporting Phase 3 dat...
|
|
Medivation Announces Fourth Quarter and Year-End 2010 Financial Results Teleconference and Webcast on March, 16 2011
Mar 9, 2011
|
7.7 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/09/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2010 financial results and provide a general business update on March 16, 2011, at 4:30 p.m. Eastern Time. A press release for the fourth quarter...
|
|
Medivation Announces Participation in Upcoming Conferences
Mar 1, 2011
|
8.3 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/01/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
The Cowen and Company 31st Annual Health Care Conference on Tuesday, March 8, at 8 a.m. Eastern Time at The Boston Marriott Cop...
|
| |
American Society of Clinical Oncology's Genitourinary Cancers Symposium
AntitumorActivity of MDV3100 in Pre- and Post-Docetaxel Advanced Prostate Cancer: Long-Term Follow-Up of the Phase 1–2 Study
Feb 17, 2011
|
329.1 KB |
|
|
Medivation and Astellas Announce Positive New, Long-Term Follow-Up Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Feb 15, 2011
|
18.7 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 02/15/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced positive, new, long-term follow-up data from the Phase 1-2 trial of MDV3100 in patients with advanced prostate cancer. MDV3100 is a novel, triple-acting, oral androgen receptor antagonist. These new results showe...
|
|
Medivation and Astellas Announce Upcoming Presentation of New, Long-Term Follow-Up Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Feb 14, 2011
|
13.5 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/14/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that new, long-term, follow-up data from the Phase 1-2 trial of MDV3100 in patients with advanced prostate cancer will be presented in a poster session at the American Society of Clinical Oncology's Genitourinary Cancers S...
|
|
Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
Feb 7, 2011
|
7.5 KB |
|
| |
SAN FRANCISCO, Feb. 7, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, at 10:30 a.m. Eastern Time at the Waldorf-Astoria in New York.
Dr. Hung will provide an overview of Medivat...
|
|
Medivation Announces Participation in 29th Annual J.P. Morgan Healthcare Conference
Jan 3, 2011
|
7.5 KB |
|
| |
SAN FRANCISCO, Jan. 3, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, at 10:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.
Dr. Hung will provide an o...
|
|
Medivation Completes Enrollment in Phase 3 'CONCERT' Trial of Dimebon Added to Donepezil in Patients With Alzheimer's Disease
Dec 7, 2010
|
11.8 KB |
|
| |
SAN FRANCISCO, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that patient enrollment was completed on November 30, 2010 in the CONCERT study, a 12-month, Phase 3 clinical trial in patients with mild-to-moderate Alzheimer's disease (AD) evaluating the potential efficacy of dimebon (latrepirdine*) when added t...
|
|
Medivation and Astellas Complete Enrollment in Phase 3 Affirm Trial of MDV3100 in Advanced Prostate Cancer
Nov 29, 2010
|
12.5 KB |
|
| |
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced pros...
|
|
Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update
Nov 5, 2010
|
20.5 KB |
|
| |
SAN FRANCISCO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2010.
"In the third quarter, we began the expansion of our MDV3100 development program into earlier stage patients with the initiation of the Phase 3 ...
|
|
Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
Oct 29, 2010
|
7.3 KB |
|
| |
SAN FRANCISCO, Oct 29, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2010 financial results and provide a general business update on November 5, 2010, at 4:30 p.m. Eastern Time. A press release for the third quarter...
|
|
Medivation Announces Participation in the NewsMakers in the Biotech Industry Conference
Oct 19, 2010
|
7.3 KB |
|
| |
SAN FRANCISCO, Oct 19, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, at 10:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conferenc...
|
|
Medivation and Astellas Announce Initiation of a Second Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Sep 29, 2010
|
12.8 KB |
|
| |
SAN FRANCISCO and TOKYO, Sept 29, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antago...
|
|
Medivation Announces Participation in the UBS Global Life Sciences Conference
Sep 14, 2010
|
7.6 KB |
|
| |
SAN FRANCISCO, Sept 14, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the UBS Global Life Sciences Conference on Tuesday, September 21, at 8:30 a.m. Eastern Time at the Grand Hyatt in New York.
Dr. Hung will provide an overv...
|
|
Medivation Reports Second Quarter 2010 Financial Results and Provides Corporate Update
Aug 9, 2010
|
19.8 KB |
|
| |
SAN FRANCISCO, Aug 09, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.
"We have made positive progress in our dimebon program over the past few months," said David Hung, MD, president and chief executive off...
|
|
Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
Aug 2, 2010
|
7.8 KB |
|
| |
SAN FRANCISCO, Aug 02, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter...
|
| |
Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) 2010 Safety and Tolerability of Dimebon for up to 26 Weeks in Patients with Mild-to-Moderate Alzheimer's Disease
Jul 14, 2010
|
205.4 KB |
|
| |
American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 7, 2010
|
164.0 KB |
|
|
Medivation Reports First Quarter 2010 Financial Results and Provides Corporate Update
May 10, 2010
|
20.3 KB |
|
| |
SAN FRANCISCO, May 10, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2010.
"After thorough review of all available dimebon data, including the disappointing CONNECTION results, Medivation remains committed to d...
|
|
|